Stock Track | Evotec SE Surges 5.05% Pre-market on $5 Million Milestone Payment from Bristol Myers Squibb

Stock Track11-12

Evotec SE (EVO) saw its stock soar 5.05% in pre-market trading on Wednesday, following the announcement of a significant milestone in its partnership with Bristol Myers Squibb (BMY). The German biotech company revealed it had received a $5 million milestone payment from Bristol Myers Squibb, triggering investor enthusiasm.

The milestone payment was prompted by the U.S. Food and Drug Administration's acceptance of an investigational new drug (IND) application for a product candidate developed under the companies' protein degradation partnership. Specifically, the drug candidate is described as a cereblon E3 ligase modulator, showcasing Evotec's progress in this cutting-edge area of drug development.

Looking ahead, Evotec announced that a phase 1 clinical trial for this promising drug candidate is expected to commence next year. This development not only represents a significant step forward in Evotec's collaboration with Bristol Myers Squibb but also underscores the company's growing potential in the competitive biotech landscape. Investors appear to be reacting positively to this news, as reflected in the pre-market stock surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1185947640?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 17:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185947640","market":"us","top_or_hot":-1,"title":"Stock Track | Evotec SE Surges 5.05% Pre-market on $5 Million Milestone Payment from Bristol Myers Squibb","media":"Stock Track","content":"<p>Evotec SE (EVO) saw its stock soar 5.05% in pre-market trading on Wednesday, following the announcement of a significant milestone in its partnership with Bristol Myers Squibb (BMY). The German biotech company revealed it had received a $5 million milestone payment from Bristol Myers Squibb, triggering investor enthusiasm.</p>\n\n<p>The milestone payment was prompted by the U.S. Food and Drug Administration's acceptance of an investigational new drug (IND) application for a product candidate developed under the companies' protein degradation partnership. Specifically, the drug candidate is described as a cereblon E3 ligase modulator, showcasing Evotec's progress in this cutting-edge area of drug development.</p>\n\n<p>Looking ahead, Evotec announced that a phase 1 clinical trial for this promising drug candidate is expected to commence next year. This development not only represents a significant step forward in Evotec's collaboration with Bristol Myers Squibb but also underscores the company's growing potential in the competitive biotech landscape. Investors appear to be reacting positively to this news, as reflected in the pre-market stock surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Evotec SE Surges 5.05% Pre-market on $5 Million Milestone Payment from Bristol Myers Squibb</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Evotec SE Surges 5.05% Pre-market on $5 Million Milestone Payment from Bristol Myers Squibb\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 17:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Evotec SE (EVO) saw its stock soar 5.05% in pre-market trading on Wednesday, following the announcement of a significant milestone in its partnership with Bristol Myers Squibb (BMY). The German biotech company revealed it had received a $5 million milestone payment from Bristol Myers Squibb, triggering investor enthusiasm.</p>\n\n<p>The milestone payment was prompted by the U.S. Food and Drug Administration's acceptance of an investigational new drug (IND) application for a product candidate developed under the companies' protein degradation partnership. Specifically, the drug candidate is described as a cereblon E3 ligase modulator, showcasing Evotec's progress in this cutting-edge area of drug development.</p>\n\n<p>Looking ahead, Evotec announced that a phase 1 clinical trial for this promising drug candidate is expected to commence next year. This development not only represents a significant step forward in Evotec's collaboration with Bristol Myers Squibb but also underscores the company's growing potential in the competitive biotech landscape. Investors appear to be reacting positively to this news, as reflected in the pre-market stock surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVO","symbol_name":"Evotec SE","start_time":0,"source_url":"","article_id":"1185947640","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185947640","pubTimestamp":1762941257,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Evotec SE (EVO) saw its stock soar 5.05% in pre-market trading on Wednesday, following the announcement of a significant milestone in its partnership with Bristol Myers Squibb (BMY). The German...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVO":"Evotec SE"},"translate_title":"个股追踪|Evotec SE盘前大涨5.05%，获百时美施贵宝500万美元里程碑付款","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVO":1},"content_text":"Evotec SE (EVO) saw its stock soar 5.05% in pre-market trading on Wednesday, following the announcement of a significant milestone in its partnership with Bristol Myers Squibb (BMY). The German biotech company revealed it had received a $5 million milestone payment from Bristol Myers Squibb, triggering investor enthusiasm.\nThe milestone payment was prompted by the U.S. Food and Drug Administration's acceptance of an investigational new drug (IND) application for a product candidate developed under the companies' protein degradation partnership. Specifically, the drug candidate is described as a cereblon E3 ligase modulator, showcasing Evotec's progress in this cutting-edge area of drug development.\nLooking ahead, Evotec announced that a phase 1 clinical trial for this promising drug candidate is expected to commence next year. This development not only represents a significant step forward in Evotec's collaboration with Bristol Myers Squibb but also underscores the company's growing potential in the competitive biotech landscape. Investors appear to be reacting positively to this news, as reflected in the pre-market stock surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1185947640","isCrawlerRequest":true}